Drugs / TF2
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01273402 | Feb 2011 → Feb 2013 | colorectal cancer | Gilead Sciences | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00860860 | Jul 2009 → Oct 2011 | colorectal neoplasm | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT02300922 | Jan 2015 → Sep 2017 | colorectal cancer | Nantes University Hospital | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT01730638 | Jan 2013 → Dec 2016 | medullary thyroid gland carcinoma | Nantes University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01730612 | Dec 2012 → May 2017 | Her2-receptor negative breast cancer | Nantes University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT01221675 | Jun 2011 → Apr 2016 | non-small cell lung carcinoma, small cell lung carcinoma | Centre René Gauducheau | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02587247 | Mar 2016 → Jan 2017 | colorectal cancer | Nantes University Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TF2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01730612 ↗ |
| Modality | Monoclonal antibody | “TF2 bispecific monoclonal antibody” NCT02300922 ↗ |
| Route | Other | “D0: Injection of TF2” NCT01730612 ↗ |